Table 1 Characteristics of patients from National Capital District and Daru cohorts
Characteristic | NCD (n = 66) | Daru (n = 100) | p value |
|---|---|---|---|
Lineage | |||
 L2 (Beijing 2.2.1.1) | 57 (86%) | 95 (95%) | 0.084 |
 L4 (Euro-American mainly 4.8) | 9 (14%) | 5 (5%) | |
Age | |||
 < 18 | 6 (9%) | 16 (16%) | 0.246 |
 ≥ 18 | 58 (88%) | 82 (82%) | |
 Unknown | 2 (3%) | 2 (2%) |  |
 Median (IQR) | 33 (25–38) | 29 (20–35) |  |
Gender | |||
 Male | 30 (48%) | 48 (48%) | 0.754 |
 Female | 36 (52%) | 52 (52%) | |
Sputum smear | |||
 Positive | 17 (26%) | 80 (80%) | 0.981 |
 Negative | 4 (3%) | 20 (20%) | |
 Unknown (Inc. Isolates) | 45 (68%) | 0 |  |
Type of TB | |||
 Pulmonary* | 63 (95%) | 99 (99%) | 0.302 |
 Extrapulmonary | 3 (5%) | 1 (1%) | |
Genomic cluster** | |||
 Yes | 53 (66%) | 87 (87%) | 0.278 |
 No | 13 (34%) | 13 (13%) | |
Phenotypic resistance to first-line drugs | |||
 HR | 17 (26%) | 0 | - |
 HRE | 5 (8%) | 0 | |
 HRS | 14 (21%) | 24 (24%) | |
 HRZ | 3 (5%) | 0 | |
 HRES | 7 (11%) | 5 (5%) | |
 HRSZ | 3 (5%) | 6 (6%) | |
 HREZ | 3 (5%) | 0 | |
 HRESZ | 14 (21%) | 50 (50%) | |
 Nil | 0 | 15 (15%) | |